The safety of sublingual immunotherapy, can the rare systemic reactions be prevented?
Introduction: The safety of subcutaneous immunotherapy (SCIT), and particularly the dramatic issue of fatal reactions, has been an obstacle that limited the implementation of a therapy with unique characteristics of action on the causes of allergy. The introduction of sublingual immunotherapy (SLIT) was aimed at solving safety problems while maintaining clinical efficacy.Areas covered: For more than 20 years, SLIT has been based on allergen extracts in drops at low average doses. As evidenced by meta-analyses, the typical adverse events (AE) have consisted of local reactions in the mouth and throat. Unlike the injection route, no correlation was observed between the administered dose and AEs. The development of SLIT products in tablets, based on higher doses than drops, has somewhat changed the concept of SLIT safety. Although large trials, performed to obtain regulatory agency approval, have shown overall high safety, rare anaphylactic reactions have been described.Expert opinion: SLIT is globally safe, and no fatal reactions have ever been reported, but with currently available high biological potency products it is necessary to follow prudential rules, such as the administration of the first dose under medical supervision and the thorough education of patients to avoid taking of higher doses than recommended.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - 20(2021), 3 vom: 02. März, Seite 259-264 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cavaliere, Carlo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergen immunotherapy |
|---|
| Anmerkungen: |
Date Completed 22.04.2021 Date Revised 22.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14740338.2021.1874917 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319910229 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319910229 | ||
| 003 | DE-627 | ||
| 005 | 20231225172445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2021.1874917 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM319910229 | ||
| 035 | |a (NLM)33427529 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cavaliere, Carlo |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The safety of sublingual immunotherapy, can the rare systemic reactions be prevented? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2021 | ||
| 500 | |a Date Revised 22.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: The safety of subcutaneous immunotherapy (SCIT), and particularly the dramatic issue of fatal reactions, has been an obstacle that limited the implementation of a therapy with unique characteristics of action on the causes of allergy. The introduction of sublingual immunotherapy (SLIT) was aimed at solving safety problems while maintaining clinical efficacy.Areas covered: For more than 20 years, SLIT has been based on allergen extracts in drops at low average doses. As evidenced by meta-analyses, the typical adverse events (AE) have consisted of local reactions in the mouth and throat. Unlike the injection route, no correlation was observed between the administered dose and AEs. The development of SLIT products in tablets, based on higher doses than drops, has somewhat changed the concept of SLIT safety. Although large trials, performed to obtain regulatory agency approval, have shown overall high safety, rare anaphylactic reactions have been described.Expert opinion: SLIT is globally safe, and no fatal reactions have ever been reported, but with currently available high biological potency products it is necessary to follow prudential rules, such as the administration of the first dose under medical supervision and the thorough education of patients to avoid taking of higher doses than recommended | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allergen immunotherapy | |
| 650 | 4 | |a local reactions | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a subcutaneous | |
| 650 | 4 | |a sublingual | |
| 650 | 4 | |a systemic reactions | |
| 650 | 7 | |a Allergens |2 NLM | |
| 650 | 7 | |a Tablets |2 NLM | |
| 700 | 1 | |a Incorvaia, Cristoforo |e verfasserin |4 aut | |
| 700 | 1 | |a Begvarfaj, Elona |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Maria Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Turchetta, Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Musacchio, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Ralli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Ciofalo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Greco, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a de Vincentiis, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Masieri, Simonetta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d 2002 |g 20(2021), 3 vom: 02. März, Seite 259-264 |w (DE-627)NLM126588422 |x 1744-764X |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2021 |g number:3 |g day:02 |g month:03 |g pages:259-264 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14740338.2021.1874917 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2021 |e 3 |b 02 |c 03 |h 259-264 | ||